Prema Robinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prema Robinson has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Anirban Maitra
Departments of Pathology and Medicine, Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY, USA
1 shared publicationMiguel Muñoz
Research Laboratory on Neuropeptides, Institute of Biomedicine of Seville (IBIS), Sevilla, Spain
1 shared publicationRafael Coveñas
University of Salamanca, Institute of Neuroscience of Castilla and León (INCYL), Laboratory of Neuroanatomy of the Peptidergic Systems, Salamanca, Spain
1 shared publicationTan Hoang
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication- Zal Italia
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by Springer Nature in npj Precision Oncology
Neurokinin-1 receptor antagonism as a potential therapeutic strategy for cancer treatment; enhancing anti-tumor efficacy while mitigating treatment-related toxicities.
The Substance P/neurokinin-1 receptor (SP/NK1R) pathway plays a significant role in several cancers, including pancreatic, breast, glioblastoma, and lung malignancies. This review highlights its involvement in metastasis, angiogenesis, proliferation, resistance, and apoptosis. Aprepitant, an NK1R antagonist and approved antiemetic, shows promising anticancer and protective effects, supporting its use in combination therapies. NK1R-targeted strategies may enhance treatment efficacy while reducing chemotherapy- and radiotherapy-induced toxicities.
- 14 July 2026
- Published by Springer Nature in npj Precision Oncology
Open AccessNeurokinin-1 receptor antagonism as a potential therapeutic strategy for cancer treatment; enhancing anti-tumor efficacy while mitigating treatment-related toxicities.
The Substance P/neurokinin-1 receptor (SP/NK1R) pathway plays a significant role in several cancers, including pancreatic, breast, glioblastoma, and lung malignancies. This review highlights its involvement in metastasis, angiogenesis, proliferation, resistance, and apoptosis. Aprepitant, an NK1R antagonist and approved antiemetic, shows promising anticancer and protective effects, supporting its use in combination therapies. NK1R-targeted strategies may enhance treatment efficacy while reducing chemotherapy- and radiotherapy-induced toxicities.